NEURO-iNN
The company intend to invest in a new pharmacological per-os treatment based on proprietary, patented glutathione derivative and polyphenols from Olea europaea. This pharmaceutical formulation is supported by a robust pre-clinical rationale and by preliminary clinical evidence of efficacy in counteracting human neurodegeneration. Human longevity is strongly conditioned, in economically developed countries, by the neurodegenerative pathologies of old age.
Project Team
Project Status
Funding Opportunity
Background
These are some of our superiorities: -Natural, plant origin of the product -Safety of ingredients (per os) already assessed -Evidence of efficacy already gained by a preliminary clinical study -Strong pre-clinical rationale based on two-decades academic researches on the two active molecules -Availability of a consistent, yet not enough, budget from self-financing We have a current portfolio of nutritional supplements for physical well-being for different age groups and high intensity physical activity supplements. Innbiotec Pharma s.r.l. researches and produces innovative biomedical solutions for the well-being of people: it was born as a spin-off of the Department of Experimental and Clinical Biomedical Sciences of the University of Florence to enhance technologies developed in about 15 years of research. After a multi-year phase of development conducted internally in international collaboration with universities and research institutions, the company has structured itself in the commercial division,which already currently sells nutraceutical products on the market, and in the research and development division, where two families of molecules have been patented: 1. Glutathione thioesters with long-chain fatty acids; 2. Polyphenols of Olea Europea. Next steps: extending our IP by filing further patents carrying out safety and toxicological study on the drug for phase-I clinical trial. insurance and additional costs for patents involved in the trial
Project Details
Areas of clinical application of these compounds include neuro-degeneration (Alzheimer's disease and Parkinson's disease),non-alcoholic fatty liver disease, and acute respiratory failure. The company intends to make, as a priority, an investment in neurodegeneration articulated as follows: 1. Qualification as an ethical drug of a derived formulation of the nutraceutical product EUVITASE. For this objective it is necessary to carry out the Pharma phases 1 and 2, aimed at confirming the very positive results of a study recently conducted on patients with cognitive impairment at the Fatebenefratelli Hospital in Rome, being presented at the 25th World Congress of Neurology. The exceptional evidence obtained in the preliminary study cited above, suggests that the treatment may be highly beneficial for patients with cognitive impairment and Alzheimer's, and represent an effective safeguard for prevention in people at risk of dementia. These phase 1 and 2 trials aim to obtain data: 1. the pharmacokinetics of glutathione adduct and safety following administration of S-acyl glutathione in combination with oleuropein; 2. on the effect of administration of S-acyl glutathione in combination with oleuropein on neuropsychological performance and neurodegeneration markers in patients with early-stage Alzheimer's disease. The timing necessary for carrying out phases 1 and 2 was evaluated in 2-2.5 years. At the end of this investment, if the results are positive to confirm the preliminary study, it is intended to transfer the IP technology to a pharmaceutical company, with relevant estimated returns.